[go: up one dir, main page]

ECSP14013249A - Derivados de anilina, su preparación y su aplicación terapéutica - Google Patents

Derivados de anilina, su preparación y su aplicación terapéutica

Info

Publication number
ECSP14013249A
ECSP14013249A ECSP14013249A ECSP14013249A EC SP14013249 A ECSP14013249 A EC SP14013249A EC SP14013249 A ECSP14013249 A EC SP14013249A EC SP14013249 A ECSP14013249 A EC SP14013249A
Authority
EC
Ecuador
Prior art keywords
alkyl
preparation
derivatives
anilina
therapeutic application
Prior art date
Application number
Other languages
English (en)
Inventor
David Middlemiss
Caroline Leriche
John Feutrill
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20110306170 external-priority patent/EP2570402A1/en
Priority claimed from EP12305130.2A external-priority patent/EP2623490A1/en
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of ECSP14013249A publication Critical patent/ECSP14013249A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/84Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/02Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/64Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/59Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/68Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings containing halogen
    • C07C63/72Polycyclic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a derivados de anilina de fórmula (I), a su preparación y a su aplicación terapéutica, por ejemplo en el tratamiento de glaucoma: donde R1a represeenta H, un halógeno, un alquilo (C1-C6) o un CN; R1b representa H, un halógeno o un alquilo (C1-C6); R1c representa H o un alquilo (C1-C6); R2 representa H, un halógeno, un OH, un O-alquilo (C1-C6) o alquilo (C1-C6); R3 representa H, un halógeno, un alquilo (C1-C6), un OH, un O-alquilo (C1-C6), un CONH2 o CN; R4 representa H, un halógeno o un alquilo (C1-C6); R5 representa H o F; R7 representa H o F; R8 representa H o F; R9 representa H o un alquilo (C1-C6), o uno de sus enantiómeros.
ECSP14013249 2011-09-16 2014-03-17 Derivados de anilina, su preparación y su aplicación terapéutica ECSP14013249A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20110306170 EP2570402A1 (en) 2011-09-16 2011-09-16 Bi-aryl derivatives, their preparation and their therapeutic application
EP12305130.2A EP2623490A1 (en) 2012-02-03 2012-02-03 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma
EP12305626 2012-06-04

Publications (1)

Publication Number Publication Date
ECSP14013249A true ECSP14013249A (es) 2014-04-30

Family

ID=46889016

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP14013249 ECSP14013249A (es) 2011-09-16 2014-03-17 Derivados de anilina, su preparación y su aplicación terapéutica

Country Status (25)

Country Link
US (2) US9249085B2 (es)
EP (1) EP2755944B1 (es)
JP (2) JP2014530177A (es)
KR (1) KR20140097127A (es)
CN (1) CN103930396B (es)
AR (1) AR087814A1 (es)
AU (1) AU2012307527B2 (es)
BR (1) BR112014005935A2 (es)
CA (1) CA2848229C (es)
CL (1) CL2014000639A1 (es)
CO (1) CO6910193A2 (es)
DO (1) DOP2014000053A (es)
EA (1) EA026702B1 (es)
EC (1) ECSP14013249A (es)
GT (1) GT201400050A (es)
IL (1) IL231444A (es)
MA (1) MA35816B1 (es)
MX (1) MX347855B (es)
NI (1) NI201400021A (es)
PE (1) PE20142083A1 (es)
PH (1) PH12014500585B1 (es)
SG (1) SG11201400555SA (es)
UY (1) UY34314A (es)
WO (1) WO2013037705A2 (es)
ZA (1) ZA201401852B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2623490A1 (en) * 2012-02-03 2013-08-07 Fovea Pharmaceuticals 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma
AU2012307527B2 (en) 2011-09-16 2017-07-20 Sanofi Aniline derivatives,their preparation and their therapeutic application
RS58594B1 (sr) * 2013-12-17 2019-05-31 Lilly Co Eli Jedinjenja dimetilbenzoeve kiseline
WO2016001452A1 (en) 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
CN104530113A (zh) * 2014-12-22 2015-04-22 上海树农化工有限公司 邻氟苯甲酸类化合物及其制备方法
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
CN106905181B (zh) * 2017-04-14 2018-10-09 上海海洋大学 一种立达霉代谢产物16的合成方法
CN107162921B (zh) * 2017-05-27 2019-12-13 中国药科大学 一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
CN112920078A (zh) * 2019-12-05 2021-06-08 武汉珈汇精化科技有限公司 一种制备4-氰基苯甲酸甲酯的方法和一种制备4-氰基苯甲酸的方法
CN113651715B (zh) * 2021-09-13 2023-12-08 江苏弘和药物研发有限公司 一种一锅法合成香豆酰多巴胺的方法
CN113636949A (zh) * 2021-09-13 2021-11-12 江苏弘和药物研发有限公司 一种一锅法合成咖啡酰多巴胺的方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1920828A (en) * 1933-08-01 Amino-xylenois and process of
US1969354A (en) * 1932-08-06 1934-08-07 Squibb & Sons Inc 3-carboxy-4-alkoxy-diphenyl and salts thereof
US3671636A (en) * 1969-10-29 1972-06-20 Merck & Co Inc Methods for treating hypertension or inhibiting gastric secretion
US4564640A (en) * 1981-07-06 1986-01-14 William H. Rorer, Inc. Amidinoureas substituted in both the urea and amidino nitrogen positions
FR2673533B1 (fr) 1991-03-05 1993-06-11 Oreal Procede de teinture des fibres keratiniques associant l'isatine ou ses derives a une aniline tri-, tetra- ou pentasubstituee, et agents de teinture.
DE4430757A1 (de) 1994-08-30 1996-03-07 Boehringer Mannheim Gmbh Neue 4-Aminopyridazine, Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel
JPH08333287A (ja) 1995-06-02 1996-12-17 Fuji Yakuhin Kogyo Kk 芳香環置換アルキルカルボン酸及びアルカノール誘導体とそれらを含有する抗血栓剤
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6369271B1 (en) 1999-02-26 2002-04-09 Boehringer Ingelheim Pharma Kg Process for preparing derivatives of biphenyl-2-carboxylic acid
DE19962294A1 (de) 1999-12-23 2001-09-06 Metsae Tissue Oyj Espoo Tissue- und/oder tissueähnliches Material sowie Verfahren zu dessen Herstellung
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004007439A1 (ja) 2002-07-10 2004-01-22 Sumitomo Pharmaceuticals Co., Ltd. ビアリール誘導体
WO2004010943A2 (en) 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
WO2004056774A2 (en) 2002-12-19 2004-07-08 Neurogen Corporation Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
WO2005009539A2 (en) 2003-07-23 2005-02-03 Synta Pharmaceuticals, Corp. Compounds for inflammation and immune-related uses
MXPA06003019A (es) 2003-10-28 2006-06-23 Reddys Lab Ltd Dr Nuevos compuestos y su uso en medicina: proceso para su preparacion y composiciones farmaceuticas que los contienen.
EP1682508A1 (en) 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Phenyl derivatives as ppar agonists
JP2005179281A (ja) 2003-12-19 2005-07-07 Sumitomo Pharmaceut Co Ltd ビフェニル化合物
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
CA2560111A1 (en) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
BRPI0511173A (pt) 2004-05-17 2007-12-04 Tibotec Pharm Ltd 1-fenil-1,5-diidro-pirido-(3,2b)indol-2-onas substituìdas nas posições 6,7,8,9, de utilidade como agentes farmacêuticos antiinfecciosos
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
ATE457302T1 (de) 2004-11-24 2010-02-15 Lilly Co Eli Aromatische etherderivate als thrombin-hemmer
JP5184891B2 (ja) 2005-01-07 2013-04-17 シンタ ファーマシューティカルズ コーポレーション 炎症及び免疫に関連する用途に用いる化合物
PE20070211A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
EP1951701A2 (en) * 2005-08-09 2008-08-06 Asterand Uk Limited Ep2 receptor agonists
AU2006287521A1 (en) 2005-09-07 2007-03-15 Plexxikon, Inc. PPARactive compounds
JP4825636B2 (ja) * 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規1,2−ジヒドロキノリン誘導体
US7910742B2 (en) 2005-09-29 2011-03-22 Abbott Laboratories Survivin inhibitors
WO2007042298A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
WO2008015517A2 (en) 2006-07-28 2008-02-07 Pfizer Products Inc. Ep2 agonists
WO2008024634A1 (en) 2006-08-25 2008-02-28 Smithkline Beecham Corporation Pyrimdine compounds useful as kinase inhibitors
EP2121580A2 (en) 2006-12-26 2009-11-25 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
US8143402B2 (en) 2007-02-01 2012-03-27 Tibotec Pharmaceuticals Ltd. Polymorphic forms of a macrocyclic inhibitor of HCV
NZ580457A (en) 2007-04-06 2012-03-30 Neurocrine Biosciences Inc Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
MY160052A (en) 2007-10-05 2017-02-15 Acucela Inc Alkoxy compounds for disease treatment
AU2008338963A1 (en) 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use
WO2009098458A2 (en) 2008-02-05 2009-08-13 Asterand Uk Limited Biaryl amides
GB0802169D0 (en) 2008-02-06 2008-03-12 Ecmo Associates Ltd Extracorporeal membrane oxygenation
US8461183B2 (en) 2008-05-26 2013-06-11 Genfit PPAR agonist compounds, preparation and uses
JP2010006707A (ja) * 2008-06-24 2010-01-14 Daiichi Sankyo Co Ltd チアゼピン誘導体を含有する医薬
US8349852B2 (en) * 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
CA2758072A1 (en) * 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
EP2438037A1 (en) 2009-06-04 2012-04-11 Merz Pharma GmbH & Co. KGaA Glycine b antagonists
US20120142667A1 (en) * 2009-06-10 2012-06-07 Nigel Ramsden Pyrimidine derivatives as zap-70 inhibitors
US9090584B2 (en) * 2010-01-26 2015-07-28 Allergan, Inc. Therapeutic agents for treatment of ocular hypertension
KR101141556B1 (ko) 2010-02-25 2012-05-03 서울대학교산학협력단 퍼록시솜 증식자 활성화 수용체 리간드 셀레나졸 유도체, 이의 제조방법 및 이들 화합물의 용도
US20120316346A1 (en) 2010-02-25 2012-12-13 Snu R & Db Foundation Selenalzole derivative having ligand which activates peroxisome proliferator activated receptor (ppar), preparing method thereof and usage of the chemical compounds
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
WO2012003145A2 (en) 2010-07-02 2012-01-05 Allergan, Inc. Therapeutic agents for ocular hypertension
US8609658B2 (en) 2011-07-27 2013-12-17 Allergan, Inc. N,N-dialkylalkylenyl esters, compositions thereof, and methods for use thereof
AU2012307527B2 (en) 2011-09-16 2017-07-20 Sanofi Aniline derivatives,their preparation and their therapeutic application
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ep2受體拮抗劑之新穎2h-吲唑
JP2013166750A (ja) 2012-01-18 2013-08-29 Dainippon Sumitomo Pharma Co Ltd ビアリールアミド誘導体またはその薬理学的に許容される塩からなる医薬
AU2013227266A1 (en) 2012-02-28 2014-10-02 Piramal Enterprises Limited Phenyl alkanoic acid derivatives as GPR agonists
IN2014DN08840A (es) 2012-04-03 2015-05-22 Mitsui Chemicals Agro Inc

Also Published As

Publication number Publication date
DOP2014000053A (es) 2014-07-15
CA2848229C (en) 2019-08-27
NZ622329A (en) 2015-05-29
PH12014500585A1 (en) 2014-04-28
US9624159B2 (en) 2017-04-18
EP2755944A2 (en) 2014-07-23
CA2848229A1 (en) 2013-03-21
JP2017052777A (ja) 2017-03-16
BR112014005935A2 (pt) 2017-03-28
PE20142083A1 (es) 2014-12-30
UY34314A (es) 2013-04-30
IL231444A (en) 2017-05-29
EA201490642A1 (ru) 2014-07-30
CO6910193A2 (es) 2014-03-31
EA026702B1 (ru) 2017-05-31
WO2013037705A9 (en) 2013-09-06
JP6272976B2 (ja) 2018-01-31
CN103930396A (zh) 2014-07-16
WO2013037705A2 (en) 2013-03-21
SG11201400555SA (en) 2014-04-28
US9249085B2 (en) 2016-02-02
IL231444A0 (en) 2014-04-30
WO2013037705A3 (en) 2013-06-06
CN103930396B (zh) 2016-11-16
NI201400021A (es) 2014-04-23
ZA201401852B (en) 2015-09-30
MX347855B (es) 2017-05-16
AU2012307527B2 (en) 2017-07-20
MA35816B1 (fr) 2014-12-01
US20160199330A1 (en) 2016-07-14
US20140350019A1 (en) 2014-11-27
CL2014000639A1 (es) 2014-11-03
MX2014003206A (es) 2014-11-10
AU2012307527A1 (en) 2014-04-03
KR20140097127A (ko) 2014-08-06
EP2755944B1 (en) 2017-06-14
GT201400050A (es) 2014-12-23
PH12014500585B1 (en) 2018-09-07
JP2014530177A (ja) 2014-11-17
AR087814A1 (es) 2014-04-16

Similar Documents

Publication Publication Date Title
ECSP14013249A (es) Derivados de anilina, su preparación y su aplicación terapéutica
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
PE20150734A1 (es) Inhibidores de glucosilceramida sintasa
MX343611B (es) Composicion de control de fitoenfermedades y su uso.
CR11814A (es) Derivados de azacarbolinas, su preparacion y su utilizacion terapeutica
PE20160654A1 (es) Compuestos de inhibidor de autotaxina
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
MX2014002836A (es) Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
CO6821935A2 (es) Derivados novedosos de cefalosporinas y cmposiciones farmacéuticas de estos
BR112013018732A2 (pt) novos derivados de amida de aril-benzocicloalquila
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
CL2013003056A1 (es) Compuestos derivados de (fenil o piridin)-etinil-(piridin o pirimidin) sustituido; composición farmacéutica que los comprende; proceso de preparación de esto; y su uso en el tratamiento de la esquizofrenia o enfermedades cognitivas.
EA201290558A1 (ru) Агонисты mglu2
PH12016502534A1 (en) Azaquinazoline carboxamide derivatives
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
CO6571879A2 (es) Composición de control de fitoenfermedades y su uso
BR112013006720A2 (pt) processo para preparação de inibidores de pan-cdk da fórmula (i) e intermediários da preparação
CO6751286A2 (es) Síntesis de derivados de 2-carboxamida-cicloamino-urea
MX2015002705A (es) Compuestos de piridinona para usarse en terapia fotodinamica.
UY32448A (es) Derivados de 3-benzofuranil-indol-2-ona-3-acetamidopiperazinas sustituidos, su preparacion y su aplicacion en terapeutica
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia
UY33973A (es) Métodos de tratamiento dirigido de degeneración lobular frontotemporal.